Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s migraine forecast will answer the following questions:
Of all people with migraine, how many in each country in the developed world have been formally diagnosed?
Of all people diagnosed with migraine, how many in each country in the developed world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of migraine over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 26 migraine patient populations, including the following:
Total Prevalence of Migraine per 1,000 People Aged 15+ in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Migraine Over the Next 20 Yearsttttttttttttttt
Analysis of Total Prevalent Cases of Migraine in 2021 by Frequency of Attack
Total Prevalence of Migraine
Prevalence of Episodic Migraine
Prevalence of Chronic Migraine
Frequency of Episodic Migraine Attacks
Total Episodic Events of Migraine
Diagnosed Prevalent Cases of Migraine
Drug-Treated Prevalent Cases of Migraine
Studies Included in the Analysis of Migraine
Studies Excluded From the Analysis of Migraine
Risk / Protective Factors
Prashant Kumar, M.P.H.,Epidemiologist. Prior to joining the company, he coordinated various public health projects focused on tuberculosis, COVID, and malnutrition. He also has experience working in the health insurance domain in India, where he was involved in claims data analytics and stakeholder management. He holds an M.P.H specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai.
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.